Association between UCP3 gene polymorphisms and nonalcoholic fatty liver disease in Chinese children

Table 4 Demographic and biochemical features of subjects with and without rs1800849 variation (mean ± SD)

	Control			NAFLD
	CC (n = 92)	CT+TT (n = 107)	P value	CC (n = 133)	CT+TT (n = 116)	P value
Gender (M/F)	48/44	60/47	0.582	103/30	90/26	0.979
Body height (cm)	142.93 ± 13.08	139.38 ± 12.10	0.048	148.82 ± 12.50	147.83 ± 10.82	0.510
Body weight (kg)	35.65 ± 9.69	33.29 ± 8.51	0.070	64.42 ± 16.86	61.14 ± 12.74	0.083
BMI (kg/m2)	17.11 ± 2.00	16.86 ± 1.80	0.358	28.45 ± 3.75	27.79 ± 3.17	0.141
SBP (mmHg)	91.59 ± 8.89	91.29 ± 9.80	0.824	113.32 ± 11.74	114.84 ± 11.36	0.301
DBP (mmHg)	66.71 ± 7.11	66.13 ± 8.16	0.595	68.27 ± 9.13	68.91 ± 8.08	0.561
Waist (cm)	58.76 ± 6.45	57.00 ± 5.59	0.040	90.78 ± 10.58	88.87 ± 8.57	0.123
Hip (cm)	71.28 ± 7.84	69.06 ± 7.75	0.047	94.31 ± 9.51	93.47 ± 7.64	0.483
WHR	0.83 ± 0.05	0.83 ± 0.04	0.833	0.95 ± 0.07	0.95 ± 0.05	0.559
FBG (mmol/L)	4.91 ± 0.35	4.92 ± 0.40	0.888	5.02 ± 0.44	4.96 ± 0.36	0.245
TG (mmol/L)	4.11 ± 0.65	4.17 ± 0.67	0.519	4.32 ± 0.82	4.48 ± 0.96	0.165
HDL (mmol/L)	1.48 ± 0.29	1.55 ± 0.30	0.128	1.33 ± 0.58	1.35 ± 0.40	0.743
LDL (mmol/L)	2.18 ± 0.52	2.19 ± 0.58	0.950	2.50 ± 0.70	2.56 ± 0.75	0.457
ALT (mmol/L)	16.85 ± 6.44	16.48 ± 8.92	0.740	54.37 ± 2.07	51.43 ± 2.28	0.574
AST (mmol/L)	23.90 ± 5.54	26.07 ± 6.56	0.013	47.53 ± 36.24	46.91 ± 37.35	0.896
FINS	7.20 ± 3.34	6.62 ± 3.35	0.226	17.13 ± 2.11	14.86 ± 2.12	0.140
HOMA-IR	1.58 ± 0.75	1.45 ± 0.74	0.231	3.80 ± 2.14	3.27 ± 2.12	0.117

Analysis was conducted using t test. Statistically significant differences between groups are shown in bold. NAFLD: Nonalcoholic fatty liver disease; M: Male; F: Female; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic pressure; WHR: Waist-to-hip ratio; FBG: Fasting blood glucose; HDL: High-density lipoprotein-cholesterol; LDL: Low-density lipoprotein-cholesterol; TG: Total triglyceride; ALT: Alanine transaminase; AST: Aspartate aminotransferase; FIN: Fasting insulin; HOMA-IR: Homeostasis model assessment-estimated insulin resistance.